Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00425477 · FLOW

Participant flow

Bexarotene and GM-CSF in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia · Source last updated 2018-10-05

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups
  1. description
    BEX and GM-CSF were administered in 4 week cycles. BEX was given orally with food daily for 28 days at the FDA-approved dose for treatment of CTCL of 300 mg/m2 and GM-CSF was given at a daily dose of 125 µg/m2 subcutaneously for 28 days.
    id
    FG000
    title
    Bexarotene + GM-CSF
periods
  1. milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        26
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        13
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        13
      type
      NOT COMPLETED
    title
    Overall Study
Complete source fields
groups
  1. description
    BEX and GM-CSF were administered in 4 week cycles. BEX was given orally with food daily for 28 days at the FDA-approved dose for treatment of CTCL of 300 mg/m2 and GM-CSF was given at a daily dose of 125 µg/m2 subcutaneously for 28 days.
    id
    FG000
    title
    Bexarotene + GM-CSF
periods
  1. milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        26
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        13
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        13
      type
      NOT COMPLETED
    title
    Overall Study

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice